Genmab Reports FDA Submission Of Supplemental Biologics License Application For Daratumumab In Combo With Bortezomib, Thalidomide, Dexamethasone, Says J&J Sees Publishing Detailed Data From Phase 3 CASSIOPEIA Study This Year
Benzinga Newsdesk